RxDoctor Payments Data

Jenny Lu, MD

Family Medicine · Middletown, NYNPI 1396784070

Payments from drug & device makers

$16,038in general payments, 2019–2025

Across 711 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$2K
  • Lilly USA, LLC$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Boehringer Ingelheim$972
  • Novo Nordisk$845
  • plus $7K from 32 others

What the payments were for

  • Food & beverage$15,81299%
  • Education$2261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,038 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$243,078
Medicare patients
251
Services billed
2,396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide51$67,610
EliquisApixaban111$46,534
OxycontinOxycodone Hcl12$37,516
MounjaroTirzepatide26$31,231
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl156$26,584
XareltoRivaroxaban61$22,736
JardianceEmpagliflozin13$22,321
JanuviaSitagliptin Phosphate32$20,835
FarxigaDapagliflozin Propanediol20$19,497
OzempicSemaglutide13$18,847
TrintellixVortioxetine Hydrobromide34$17,947
Xtampza ErOxycodone Myristate13$15,938
EntrestoSacubitril/Valsartan34$13,524
Fentanyl58$11,320
Tresiba Flextouch U-100Insulin Degludec21$8,720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,298$98,84077 claims
PfizerEliquis$604$46,534111 claims
MerckJanuvia, Belsomra$155$24,22544 claims
Johnson & JohnsonXarelto$756$22,73661 claims
Boehringer IngelheimJardiance$972$22,32113 claims
AstraZenecaFarxiga$1,702$19,49720 claims
Novo NordiskOzempic$845$18,84713 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$513$17,94734 claims
Collegium Pharmaceutical, Inc.Xtampza Er$131$15,93813 claims
NovartisEntresto$116$13,52434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.

Other family medicine in Middletown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →